

Special Issue

Current Advances in Lung Cancer Diagnosis and Treatment

Message from the Guest Editors

Remarkable advances in systemic agents, such as targeted therapies and immuno-oncological agents, are significantly changing the treatment methods for lung cancer patients based on the stage they are in. In particular, this enables more aggressive local therapy in the treatment of stage IV lung cancer. The current National Comprehensive Cancer Network guidelines also recommend consolidative local therapy for selected patients with localized metastatic lung cancer who have responded to prior chemotherapy and have a limited extra-thoracic tumor burden. However, in actual clinical settings, there are still no consistent treatment principles for defining criteria for localized metastasis, as well as for evaluating and treating oligo-progression. In active local treatment, it is important to consider the patient's general condition, such as the presence of any underlying lung disease and the potential side effects of the treatment. In this Special Issue, we will compile studies related to improving clinical outcomes or predicting side effects, aligned with the latest knowledge on lung cancer treatment.

Guest Editors

Dr. Hakyoung Kim

Dr. Daesik Yang

Dr. Zhiwei Hu

Deadline for manuscript submissions

30 June 2026



Life

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 6.0
Indexed in PubMed



mdpi.com/si/221833

Life
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
life@mdpi.com

[mdpi.com/journal/
life](https://mdpi.com/journal/life)





Life

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
life](https://mdpi.com/journal/life)



About the Journal

Message from the Editor-in-Chief

Life (ISSN 2075-1729) is an international, peer-reviewed open access journal that publishes scientific studies related to fundamental themes in life sciences. Some papers are published individually, while others are submitted for inclusion in special issues with guest editors. You are invited to contribute a research article, essay, or a review to be considered for publication.

Editor-in-Chief

Prof. Dr. Lluís Ribas de Pouplana

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona
Institute of Science and Technology, 08028 Barcelona, Spain

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biology) / CiteScore - Q1 (Paleontology)